NEW YORK, Jan. 6 (GenomeWeb News) - Invitrogen has acquired Morphotek's cell line evolution service business for an undisclosed amount, the company said yesterday.
Under the transaction, Morphotek retained rights to its Human Morphodoma antibody technology platform.
According to Nicholas Nicolaides, Morphotek's president and CEO, funding from this transaction will support current clinical trials as well as future therapeutic candidates.
Invitrogen is now the exclusive provider of the cell line evolution technology, Revolution, to the biotechnology and agricultural industries, Morphotek said.
Financial terms were not disclosed.